Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia?

L Pyrkosch, J Mumm, I Alt, L Fehm, T Fydrich, J Plag, A Ströhle

Journal: Journal of psychiatric research 2019;105():153-163

PMID: 30237105

Full Text on Elsevier Science View on PubMed

Abstract

The use of d-cycloserine (DCS) to augment exposure based therapy for anxiety disorders has shown mixed, although overall positive effects. Aim of the present study was to examine post-exposure administration of DCS in patients with agoraphobia with or without panic disorder. 73 patients with agoraphobia (with or without panic disorder) were treated with 12 sessions of cognitive behavioral therapy (CBT) including 3 exposures. Following successful exposure patients were given double blind either placebo or 50 mg of DCS. Primary outcome criterion was change in the Panic and Agoraphobia Scale (PAS) between CBT session t1, t4 (+∼2 months), t10 (+∼3 months) und t11 (+∼4 months). During the course of CBT the patients' symptomatology decreased significantly as measured by primary and secondary outcome criteria, however, without an additional benefit for DCS treated patients. Exploratory sub-group analyses for severely ill patients and patients with high anxiety and strong habituation during exposure showed that DCS administration was associated with increased improvement during the 1-month follow-up period (t10 - t11) with medium to large effect sizes (range in effect size η from .06 to .25). Our study results are consistent with recent research on DCS, indicating a beneficial augmentative effect for sub-groups of anxiety patients. The lack of an overall DCS effect for the whole patient sample might be explained by a dual mechanism in fear conditioning and extinction with different cognitive processes being involved during exposure depending on the degree of anxiety experienced by the patient.

Address: Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Germany. Electronic address: [email protected].; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Germany. Electronic address: [email protected].; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Germany. Electronic address: [email protected].; Centre of Psychotherapy at the Department of Psychology, Humboldt-Universität zu Berlin, Germany. Electronic address: [email protected].; Centre of Psychotherapy at the Department of Psychology, Humboldt-Universität zu Berlin, Germany. Electronic address: [email protected].; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Germany. Electronic address: [email protected].; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Germany. Electronic address: [email protected].

DOI: 10.1016/j.jpsychires.2018.08.016

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/30237105

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD38-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Agoraphobia, Cognitive Behavioral Therapy, Combined Modality Therapy, Cycloserine, Excitatory Amino Acid Agonists, Extinction, Psychological, Female, Follow-Up Studies, Humans, Implosive Therapy, Male, Middle Aged, Outcome Assessment, Health Care, Panic Disorder, Receptors, N-Methyl-D-Aspartate